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We found with Diltiazem a close correlation between the SBP values
and the SBP decrease with a correlation coefficient 5 0.6 and a 2-tailed
p , 0.0001 (Pearson’s correlation).
Diltiazem 180 mg in slow release capsules has a proportional effect on
blood pressure evaluated by 24 hour ABPM: it produces a proportional
decrease in the elevated blood pressure without inducing hypotension
when patients present normal or low blood pressure values.
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TREATMENT OF ISOLATED SYSTOLIC
HYPERTENSION IN A COMPARATIVE STUDY OF
FOUR ANTIHYPERTENSIVE DRUGS
Pantelis E. Zebekakis, John Tziolas, Anastasios N. Lasaridis, Achilleas
A. Tourkantonis. 1First Depart of Internal Medicine, AHEPA
University Hospital, Thessaloniki1, Greece
To perform a comparative study of monotherapy or, if necessary, com-
bination treatment for isolated systolic hypertension (ISH) with a di-
uretic, b-blocker, ACE inhibitor and calcium antagonist, we have studied
in this non-blind, randomized study with four parallel treatment groups in
outpatients hypertensives recruited from our antihypertensive clinic from
January 96 to December 99. Patients after a 2-week washout period
received 2.5/25 to 5/50 mg amiloride/chlorthalidone, 50 to 100 mg
atenolol, 2-4 mg perindopril, or 5 to 10 mg felodipine, daily in the
morning. Random measurements of resting blood pressure was used to
monitor therapy and was performed 22 to 24 hours after taking the
medication and every 4 weeks for 3 months. The aim of the treatment
was to achieve an SBP ,140 mmHg. If this was not reached after 4
weeks of monotherapy, then dual therapy was given with a combination
of the study drugs. Triple therapy was instituted after a further 4 weeks,
if required.The study included 1375 patients with essential hypertension,
106 (7.7%) of them found with ISH (systolic blood pressure SBP./5
140 mmHg, diastolic blood pressure ,90 mm Hg), 40 of which were
males (37%). The mean age was 62.9 years and the body mass index 28.7
kg/m2. The four groups were consisted of about 25 patients with com-
parable basic characteristics. Only 96 patients, seventy of them (66%)
over 60 years old completed the study, because 10 of them dropped out
(2 with cough and 8 with peripheral edema). The antihypertensive effect
of each drug, after 4 weeks of monotherapy was comparable and signif-
icant (mean SBP/DBP: felt from 160.6/81.5 to 143.2/74.4 mmHg, p,0
.001). The target SBP (SBP,140 mmHg) with monotherapy achieved 70
(73%) patients, 22 (88%) on felodipine, 15 (65%) on atenolol, 18 (75%)
on amiloride/chlorthalidone and 15 patients (62%) on perindopril. Sev-
enteen patients (27%) required dual therapy, and 9 (9.3%) needed triple
therapy.
In descending order, the dihydropyridine calcium antagonist felodip-
ine, the diuretic amiloride/chlorthalidone, the b-blocker atenolol and the
ACE inhibitor perindopril, as single and combination therapy proved
suitable for reducing blood pressure effectively for 24 hours in ISH, and
were well tolerated.
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BETA-BLOCKADE WITH NEBIVOLOL ENHANCES
THE ACETYLCHOLINE-INDUCED VASODILATION IN
THE CUTANEAOUS VASCULAR BED OF
NORMOTENSIVE VOLUNTEERS
Sandrine Kubli, Feihl Francois, Bernard Waeber. 1University
Hospital, Division of Pathophysiology, Lausanne, Switzerland
This study was undertaken to assess whether the beta1-adrenoceptor
blocker nebivolol(N) increases the vasodilatory response to acetylcho-
line(Ach) when administered orally to healthy subjects. To this end 12
volunteers were randomly allocated to a 8-day treatment with nebivolol
(n), 5 mg once a day, and atenolol(A),50 mg once a day, according to a
cross-over design, with a 1 week wash-out period between the two
treatment phases. The forearm skin blood flow(SBF) response to Ach
applied by iontophoresis was determined using a laser-Doppler scanner
imaging system before(T0) and 3 hours(T3) after N or A dosing, both on
the first (Day 1) and the last day (Day 8) of treatment. The following
Table shows the responses of SBF (perfusion units) (means6SD;
*p,0.05 versus T0):
Day 1 Day 8
T0 T3 T0 T3
Nebivolol 98693 4416109* 3936110 4266105*
Atenolol 396697 410699 3806109 394698
Iontophoresis of 0.09% NaCl had no effect on SBF. These data
indicate that nebivolol (administered at a dose commonly used in clinical
practice), but not atenolol, enhances in humans the vasorelaxant activity
of Ach in the skin vascular bed, which is compatible with a facilitation
by this beta-blocker of the endothelium-dependent vasodilation.
Key Words: Beta-adrenoceptor blockade, Endothelial function, Skin mi-
crocirculation
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THE S-NITROSO DERIVATIVE OF OMAPATRILAT
(VANLEV) CAN ACT AS A SUBSTRATE FOR CELL
SURFACE PROTEIN DISULFIDE ISOMERASE AND
THUS DELIVER NO TO THE CYTOSOL OF HUMAN
UMBILICAL ENDOTHELIAL CELLS,IN VITRO
Bulent Mutus, Okechukwu Ukairo, Paul Root, Raphael Cheung.
1Chemistry & Biochemistry, University of Windsor, Windsor, ON,
Canada
Background: Omapatrilat (Vanlev) is a new vasopeptidase inhibitor. It
simultaneously inhibits two key enzymes involved in the regulation of
cardiovascular function, neutral endopeptidase and angiotensin-convert-
ing enzyme. Omapatrilat contains a free thiol group that can potentially
act as a nitric oxide (NO)-carrier. In this study, we explored the ability
Omapatrilat-NO to donate NO to the cytosol of by acting as a substrate
for the enzyme cell-surface protein disufide isomerase.
Methods: These dynamic microscopy studies, were conducted on live
human umbilical vein endothelial cells in vitro, with the aid of fluores-
cent intracellular NO-probe dansylhomocysteine. With this compound
the kinetics of cell-surface protein disulfide isomerase-catalyzed NO
transfer from S-nitrosothiols, like Omapatrrilat-NO can be directly eval-
uated. The levels of cell-surface protein disulfide isomerase protein, were
also monitored as a function of Omapatrilat by Western blotting.
Results: The estimated KM of cell-surface protein disulfide isomerase
for Omapatrilat-NO, in the presence of 10 micromolar Omapatrilat was
40 micromolar. When the kinetics were repeated after a 24 h pretreatment
of the cells with 10 micromolar Omapatrilat, the KM decreased by
30-fold to 1.4 micromolar. Western blot analysis of secreted protein
disulfide isomerase, indicated that the amount of protein also increased
by nearly 5-fold upon a 24h incubation with Omapatrilat.
Conclusion: These studies show that the NO derivative of Omapatrilat
is stable and can donate its NO to the cytosol through the action of the
enzyme cell-surface protein disufide isomerase. These studies also dem-
onstrate that Omapatrilat can affect the affinity of the enzyme as well as
upregulating its excreteion by and unknown mechanism. The results
presented here indicate that apart from vasopeptidase inhibiton, Omapat-
rilat could potentially act as a vasodilator by its ability to carry NO and
to positively affect the enzyme resposible for the release of S-nitroso-
thiol-bound NO into the cells comprizing the vasculature.
Key Words: S-Nitroso derivative of omapatrilat, Endothelial NO-metab-
olism, Cell surface protein-disufide isomerase
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